INCY vs ROIV
Incyte and Roivant Sciences Ltd., both Healthcare
Roivant Sciences Ltd. is the larger company at $24B against $20B. Over the past year ROIV returned +136% against +31% for INCY. The RyuScore puts INCY ahead, 82 against 42 out of 100.
| Figure | INCY | ROIV |
|---|---|---|
| Last close | $113 | $35.42 |
| Market cap | $20B | $24B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 15.9 | n/a |
| 1-year return | +31% | +136% |
| 5-year return | +56% | +255% |
| RyuScoresector-relative, 1–10 | 82/100 | 42/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Incyte
Revenue of $1.3B in Q1 2026, net income $303M. Its largest reported line is JAKAFI, 48% of the disclosed total.
Roivant Sciences Ltd.
Revenue of $1M in Q1 2026, net income null.
Open these two in the interactive comparison to add more names, change the period or see the correlation.